http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Oct 2025 02:44:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/Press+Releases/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html <div class="xn-content"> <p><location value="LU/de..berlin" idsrc="xmltag.org" >BERLIN</location>, <span class="legendSpanClass"><chron>Oct. 20, 2025</chron></span> /PRNewswire/ -- At the 2025 <span>European Society for Medical Oncology (ESMO) Congress</span>, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by <span value="Shanghai:688331" idsrc="xmltag.org" >RemeGen Co., Ltd.</span> was presented at the Presidential Symposium by Professor <person>Jun Guo</person> from <span>Beijing Cancer Hospital</span>. It's the first time a research led by Chinese scholars in the field of urological oncology has http://www.streetinsider.com/PRNewswire/ESMO+Congress+2025+Presidential+Symposium+Oral+Presentation+%7C+Disitamab+Vedotin+Achieves+Major+Breakthrough+as+First-Line+Treatment+for+Urothelial+Carcinoma/25472792.html Mon, 20 Oct 2025 02:44:00 -0500 688331 9995 A.09649487 O.00048429 O.33620320 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/Press+Releases/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html <div class="xn-content"> <ul type="disc"> <li>In the results of China Phase III clinical trial announced at the 2025 ACR, Telitacicept demonstrated statistically significant and clinically meaningful improvements in ESSDAI [EULAR (<span value="ACORN:5020225866" idsrc="xmltag.org" >European League Against Rheumatism</span>) Sjögren's Syndrome Disease Activity Index] compared to placebo.</li> <li>Telitacicept met the primary endpoint and all http://www.streetinsider.com/PRNewswire/2025+ACR+Abstract+Released%21+Exciting+Data+from+Telitacicept%27s+Phase+III+Clinical+Study+in+Sj%C3%B6gren%27s+Syndrome+in+China/25448663.html Tue, 14 Oct 2025 01:40:00 -0500 688331 9995 A.06822034 A.50202258 O.20026344 O.33620320 O.41910163 REGMY